Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324333886> ?p ?o ?g. }
- W4324333886 endingPage "180" @default.
- W4324333886 startingPage "171" @default.
- W4324333886 abstract "Purpose 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) parameters are prognostic of oncologic outcomes in human papillomavirus–associated oropharyngeal squamous cell carcinoma (OPSCC). We used FDG-PET imaging biomarkers to select patients for de-escalated chemoradiotherapy (CRT), hypothesizing that acute toxicity will be improved with de-escalation. Methods and Materials This is a planned interim initial feasibility and acute toxicity report from a phase 2, prospective, nonrandomized study, which enrolled patients with stage I-II p16+ OPSCC. All patients started definitive CRT to 70 Gy in 35 fractions, and those who met de-escalation criteria on midtreatment FDG-PET at fraction 10 completed treatment at 54 Gy in 27 fractions. We report the acute toxicity and patient-reported outcomes for 59 patients with a minimum follow-up of 3 months. Results There were no statistically significant differences between baseline patient characteristics in the standard and de-escalated cohorts. There were 28 of 59 (47.5%) patients who met FDG-PET de-escalation criteria and collectively received 20% to 30% less dose to critical organs at risk known to affect toxicity. At 3 months posttreatment, patients who received de-escalated CRT lost significantly less weight (median, 5.8% vs 13.0%; P < .001), had significantly less change from baseline in penetration-aspiration scale score (median, 0 vs 1; P = .018), and had significantly fewer aspiration events on repeat swallow study (8.0% vs 33.3%, P = .037) compared with patients receiving standard CRT. Conclusions Approximately half of patients with early-stage p16+ OPSCC are selected for de-escalation of definitive CRT using midtreatment FDG-PET biomarkers, which resulted in significantly improved rates of observed acute toxicity. Further follow-up is ongoing and will be required to determine whether this de-escalation approach preserves the favorable oncologic outcomes for patients with p16+ OPSCC before adoption. 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) parameters are prognostic of oncologic outcomes in human papillomavirus–associated oropharyngeal squamous cell carcinoma (OPSCC). We used FDG-PET imaging biomarkers to select patients for de-escalated chemoradiotherapy (CRT), hypothesizing that acute toxicity will be improved with de-escalation. This is a planned interim initial feasibility and acute toxicity report from a phase 2, prospective, nonrandomized study, which enrolled patients with stage I-II p16+ OPSCC. All patients started definitive CRT to 70 Gy in 35 fractions, and those who met de-escalation criteria on midtreatment FDG-PET at fraction 10 completed treatment at 54 Gy in 27 fractions. We report the acute toxicity and patient-reported outcomes for 59 patients with a minimum follow-up of 3 months. There were no statistically significant differences between baseline patient characteristics in the standard and de-escalated cohorts. There were 28 of 59 (47.5%) patients who met FDG-PET de-escalation criteria and collectively received 20% to 30% less dose to critical organs at risk known to affect toxicity. At 3 months posttreatment, patients who received de-escalated CRT lost significantly less weight (median, 5.8% vs 13.0%; P < .001), had significantly less change from baseline in penetration-aspiration scale score (median, 0 vs 1; P = .018), and had significantly fewer aspiration events on repeat swallow study (8.0% vs 33.3%, P = .037) compared with patients receiving standard CRT. Approximately half of patients with early-stage p16+ OPSCC are selected for de-escalation of definitive CRT using midtreatment FDG-PET biomarkers, which resulted in significantly improved rates of observed acute toxicity. Further follow-up is ongoing and will be required to determine whether this de-escalation approach preserves the favorable oncologic outcomes for patients with p16+ OPSCC before adoption." @default.
- W4324333886 created "2023-03-16" @default.
- W4324333886 creator A5005727025 @default.
- W4324333886 creator A5010705251 @default.
- W4324333886 creator A5012697039 @default.
- W4324333886 creator A5012790496 @default.
- W4324333886 creator A5022036818 @default.
- W4324333886 creator A5027649222 @default.
- W4324333886 creator A5031993983 @default.
- W4324333886 creator A5037249246 @default.
- W4324333886 creator A5037580244 @default.
- W4324333886 creator A5039039295 @default.
- W4324333886 creator A5044994112 @default.
- W4324333886 creator A5053392688 @default.
- W4324333886 creator A5060316016 @default.
- W4324333886 creator A5061980949 @default.
- W4324333886 creator A5062247384 @default.
- W4324333886 creator A5063061362 @default.
- W4324333886 creator A5067694439 @default.
- W4324333886 creator A5070289110 @default.
- W4324333886 creator A5081161607 @default.
- W4324333886 creator A5083322184 @default.
- W4324333886 creator A5087804427 @default.
- W4324333886 date "2023-09-01" @default.
- W4324333886 modified "2023-10-02" @default.
- W4324333886 title "Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial of 18F-Fluorodeoxyglucose Positron Emission Tomography Response-Based De-escalated Definitive Chemoradiotherapy for p16+ Oropharynx Cancer: A Planned Interim Analysis" @default.
- W4324333886 cites W1842042263 @default.
- W4324333886 cites W1909224217 @default.
- W4324333886 cites W1967494799 @default.
- W4324333886 cites W1985273065 @default.
- W4324333886 cites W1994747484 @default.
- W4324333886 cites W2013179608 @default.
- W4324333886 cites W2034989766 @default.
- W4324333886 cites W2063547370 @default.
- W4324333886 cites W2104783586 @default.
- W4324333886 cites W2113092282 @default.
- W4324333886 cites W2130068955 @default.
- W4324333886 cites W2142162970 @default.
- W4324333886 cites W2144693734 @default.
- W4324333886 cites W2149020191 @default.
- W4324333886 cites W2313665888 @default.
- W4324333886 cites W2339757106 @default.
- W4324333886 cites W2411293912 @default.
- W4324333886 cites W2519921049 @default.
- W4324333886 cites W2553229209 @default.
- W4324333886 cites W2562545745 @default.
- W4324333886 cites W2566106337 @default.
- W4324333886 cites W2601989107 @default.
- W4324333886 cites W2607491790 @default.
- W4324333886 cites W2889843738 @default.
- W4324333886 cites W2899132665 @default.
- W4324333886 cites W2902299732 @default.
- W4324333886 cites W2948644893 @default.
- W4324333886 cites W2968987551 @default.
- W4324333886 cites W3048439355 @default.
- W4324333886 cites W3049505140 @default.
- W4324333886 cites W3092754893 @default.
- W4324333886 cites W3119504480 @default.
- W4324333886 cites W3122345229 @default.
- W4324333886 cites W3165016332 @default.
- W4324333886 cites W3211020881 @default.
- W4324333886 cites W4206713577 @default.
- W4324333886 cites W4207009775 @default.
- W4324333886 cites W4226339397 @default.
- W4324333886 doi "https://doi.org/10.1016/j.ijrobp.2023.03.043" @default.
- W4324333886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36931572" @default.
- W4324333886 hasPublicationYear "2023" @default.
- W4324333886 type Work @default.
- W4324333886 citedByCount "1" @default.
- W4324333886 crossrefType "journal-article" @default.
- W4324333886 hasAuthorship W4324333886A5005727025 @default.
- W4324333886 hasAuthorship W4324333886A5010705251 @default.
- W4324333886 hasAuthorship W4324333886A5012697039 @default.
- W4324333886 hasAuthorship W4324333886A5012790496 @default.
- W4324333886 hasAuthorship W4324333886A5022036818 @default.
- W4324333886 hasAuthorship W4324333886A5027649222 @default.
- W4324333886 hasAuthorship W4324333886A5031993983 @default.
- W4324333886 hasAuthorship W4324333886A5037249246 @default.
- W4324333886 hasAuthorship W4324333886A5037580244 @default.
- W4324333886 hasAuthorship W4324333886A5039039295 @default.
- W4324333886 hasAuthorship W4324333886A5044994112 @default.
- W4324333886 hasAuthorship W4324333886A5053392688 @default.
- W4324333886 hasAuthorship W4324333886A5060316016 @default.
- W4324333886 hasAuthorship W4324333886A5061980949 @default.
- W4324333886 hasAuthorship W4324333886A5062247384 @default.
- W4324333886 hasAuthorship W4324333886A5063061362 @default.
- W4324333886 hasAuthorship W4324333886A5067694439 @default.
- W4324333886 hasAuthorship W4324333886A5070289110 @default.
- W4324333886 hasAuthorship W4324333886A5081161607 @default.
- W4324333886 hasAuthorship W4324333886A5083322184 @default.
- W4324333886 hasAuthorship W4324333886A5087804427 @default.
- W4324333886 hasConcept C121608353 @default.
- W4324333886 hasConcept C126322002 @default.
- W4324333886 hasConcept C188816634 @default.
- W4324333886 hasConcept C2775842073 @default.
- W4324333886 hasConcept C2777415128 @default.
- W4324333886 hasConcept C2778424827 @default.
- W4324333886 hasConcept C29730261 @default.